

## Latest Results of the STAR Breast Cancer Prevention Trial

D Lawrence Wickerham, MD  
Associate Chairman  
NSABP

---

---

---

---

---

---


---

---

## 2010 Breast Cancer Estimates

207,090 New Cases

39,840 Deaths



2010, American Cancer Society, Inc., SEER; Jemal A, et al. CA Cancer J Clin. 2010 epub

---

---

---

---

---

---

---

---

# NSABP

*National Surgical Adjuvant  
Breast and Bowel Project*

---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---

---

---

---

---

---

- Gail Model Variables Used to Provide Composite Risk Assessment**
- No. 1st degree female relatives with breast cancer
  - Nulliparity or age at 1st live birth
  - No. of benign breast biopsies
  - Atypical hyperplasia
  - Age at menarche
  - Race

---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---

---


---

---

---

---

### Chemical Structure



Tamoxifen

Raloxifene

NSABP P-2

---

---

---

---


---

---

---

---

### NSABP STAR Schema



---

---

---

---

---

---

---

---

### RESULTS

---

---

---


---

---

---

---

---



---

---

---

---

---


---

---

---

---

---



---

---

---

---

---


---

---

---

---

---



---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

---

---

### P-2 STAR Hysterectomy\* and Endometrial Hyperplasia

	No. of Events		Risk Ratio (RR)	RR 95% Confidence Interval
	Tam	Ral		
Hysterectomy*	349	162	0.45	0.37 to 0.54
Hyperplasia*	126	25	0.19	0.12 to 0.29
With atypia*	22	4	0.17	0.04 to 0.51
Without atypia*	104	21	0.19	0.11 to 0.31

\*Among women not diagnosed with uterine cancer

NSABP  
AACR 4-10

---

---

---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

---

---

- ### P-2 STAR Conclusions
- With a median follow-up of 81 months
    - Tamoxifen is more effective than Raloxifene in reducing the risk of both invasive and non-invasive breast cancer among postmenopausal women at increased risk
  - Raloxifene retains 76-78% of Tamoxifen's chemoprevention benefits with significantly fewer
    - Endometrial cancers
    - Thromboembolic events and
    - Cataracts
  - Raloxifene remains an important option for postmenopausal women who wish to reduce their risk of breast cancer

---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

---

---





**Profiles of Potential  
Candidates for Breast Cancer  
Chemoprevention**

---

---

---

---

---

---

---

---

Women who are **ALREADY** taking  
raloxifene (Evista®) for their bones

---

---

---

---

---

---

---

---

**Women with biopsy proven:**

- Atypical hyperplasia of the breast
- **OR**
- Lobular carcinoma-in-situ (LCIS)

---

---

---

---

---

---

---

---

Post-menopausal women with  
osteoporosis **AND** risk factors for  
breast cancer

---

---

---

---

---

---

---

---



---

---

---

---

---

---

---

---